The post hoc analysis investigated treatment responses in a patient subgroup with moderate to severe Chronic Hand Eczema (CHE) treated with delgocitinib cream for 16 weeks in the DELTA 1 2 phase 3 trials.1 Late-breaking presentation showcased that delgocitinib cream produced a deep, consistent and/or maintained response in a subgroup of patients with moderate to … [Read more…]
No drug associated adverse effects were reported Oral drug was well tolerated, and no clinically significant findings or safety concerns were noted Escalation to the second dose cohort of this single ascending dose study continues per protocol BIRMINGHAM, Ala.–(BUSINESS WIRE)–TIXiMED Inc. (www.tiximed.com), a clinical-stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an … [Read more…]
ROSEMONT, Ill.–(BUSINESS WIRE)–#3DEpitopeMapping–Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product characterization for primary antibody targets on its website (ptglab.com). The advanced validation data, 3D Epitope Mapping, is designed to enhance the efficiency and accuracy of antibody-related selection, empowering scientists with the data they need to advance their … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “IVD Assay Development Market Size, Share, Forecast, & Trends Analysis by Offering Technology, Application – Global Forecast to 2031” report has been added to ResearchAndMarkets.com’s offering. The global IVD assay development market is projected to reach $8.39 billion by 2031 at a CAGR of 7.9% from 2024 to 2031. The growth of this … [Read more…]
MONTREAL–(BUSINESS WIRE)–Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity reinforces the company’s dual focus on rheumatology and dermatology and recognizes the close synergy between these fields. Innovaderm has over 25 years of clinical research experience within dermatology, and recognizes that … [Read more…]
MATTERHORN is first global, randomized Phase III trial to demonstrate superior event-free survival with an immunotherapy combination over standard of care in this setting IMFINZI plus chemotherapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023 WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from the MATTERHORN Phase III trial showed … [Read more…]
MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the enrollment of the last patient in its NOTOXIS Proof of Concept (POC) Phase 2a clinical trial of SENS-401 for the prevention of Cisplatin-Induced Ototoxicity … [Read more…]
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission’s (“FTC” or the “Agency”) announcement that it will challenge the proposed acquisition of Surmodics (the “Merger”) by funds affiliated with GTCR … [Read more…]
Prestigious Award Recognizes the Company’s Commitment to Total Human Health and Mental Health Awareness EL PASO, Texas–(BUSINESS WIRE)–Jordan Foster Construction (JFC) is honored to receive the 2025 Construction Working Minds Mental Health Visionary Award for its commitment to advancing mental health awareness and strengthening total human health in the construction industry. The Mental Health Visionary … [Read more…]
PHOENIX–(BUSINESS WIRE)–#Arizona–Arizona bioscience companies Anuncia Medical and Macula Vision Systems have been selected from a competitive field of startups to receive funding support through the 2025 Flinn Foundation Bioscience Entrepreneurship Program. The companies receive $100,000 in non-dilutive funding support through the Arizona Bioindustry Association, the Foundation’s nonprofit partner. In addition, they can access professional and … [Read more…]
